MC4R raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-13 and is reviewed periodically as new material appears.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide backbone |
| Molecular mass | Approximately 1025 Da | Nominal mass of the free peptide |
| Appearance | White to off-white lyophilised powder | Typical for purified synthetic peptides |
| Solubility class | Freely soluble in water | Organic solubility is limited |
| Typical storage temperature | −20 °C or below | Protect from moisture and light |
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
Lymph vessels called lacteals are at the beginning of the gastrointestinal tract, predominantly in the small intestine. While most other nutrients absorbed by the small intestine are passed on to the portal venous system to drain via the portal vein into the liver for processing, fats (lipids) are passed on to the lymphatic system to be transported to the blood circulation via the thoracic duct. (There are exceptions, for example, medium-chain triglycerides are fatty acid esters of glycerol that passively diffuse from the GI tract to the portal system.) The enriched lymph originating in the lymphatics of the small intestine is called chyle. The nutrients that are released into the circulatory system are processed by the liver, having passed through the systemic circulation.
==== Dependence and withdrawal ==== Tolerance is expected to develop with regular methamphetamine use and, when used recreationally, this tolerance develops rapidly. In dependent users, withdrawal symptoms are positively correlated with the level of drug tolerance. Depression from methamphetamine withdrawal lasts longer and is more severe than that of cocaine withdrawal. According to the current Cochrane review on drug dependence and withdrawal in recreational users of methamphetamine, "when chronic heavy users abruptly discontinue [methamphetamine] use, many report a time-limited withdrawal syndrome that occurs within 24 hours of their last dose". Withdrawal symptoms in chronic, high-dose users are frequent, occurring in up to 87.6% of cases, and persist for three to four weeks with a marked "crash" phase occurring during the first week. Methamphetamine withdrawal symptoms can include anxiety, drug craving, dysphoric mood, fatigue, increased appetite, increased movement or decreased movement, lack of motivation, sleeplessness or sleepiness, and vivid or lucid dreams. Methamphetamine that is present in a mother's bloodstream can pass through the placenta to a fetus and be secreted into breast milk. Infants born to methamphetamine-abusing mothers may experience a neonatal withdrawal syndrome, with symptoms involving of abnormal sleep patterns, poor feeding, tremors, and hypertonia. This withdrawal syndrome is relatively mild and only requires medical intervention in approximately 4% of cases.
30 May to 1 July Operation Lavarack was a reconnaissance in force conducted by the 6th Battalion, Royal Australian Regiment/Royal New Zealand Infantry Regiment (ANZAC) north of Nui Dat. The operation resulted in 102 PAVN/VC and 3 ANZACs killed.
having an acceptable treatment protocol in place that changes the outcome for patients diagnosed early with the disease an understanding of the condition's natural history an understanding about who will be treated as a patient a screening test that is reliable for both affected and unaffected patients and is acceptable to the public As diagnostic techniques have progressed, debates have arisen as to how screening programs should adapt. Tandem mass spectrometry has greatly expanded the potential number of diseases that can be detected, even without satisfying all of the other criteria used for making screening decisions. Duchenne muscular dystrophy is a disease that has been added to screening programs in several jurisdictions around the world, despite the lack of evidence as to whether early detection improves the clinical outcome for a patient.
Sources: en.wikipedia.org
=== January === 1 January Helen Hogan, educator (Hillmorton High School, WEA), editor of poetry anthologies, and Māori studies scholar (born 1923). Lyn Fleming, Police senior sergeant and first policewoman in New Zealand to be killed in the line of duty (born 1963). 2 January – Lex Clark, Olympic rower (1964) (born 1943). 3 January Kate Coolahan, commercial artist, fashion illustrator, printmaker, and design educator (Wellington Polytechnic) (born 1929). Dame Tariana Turia, politician, Labour list MP (1996–2002), MP for Te Tai Hauāuru (2002–2014), co-leader of the Māori Party (2004–2014), Minister for the Community and Voluntary Sector (2003–2004, 2008–2011), Minister for Disability Issues (2009–2014), Minister for Whānau Ora (2010–2014) (born 1944). 5 January Philippa Blair, artist (born 1945). Lou Robinson, structural engineer and heritage advocate (born 1943). 7 January – Arthur Pomeroy, classical scholar (Victoria University of Wellington), chess player and administrator (born 1953). 18 January – Russell Marshall, politician and diplomat, MP for Wanganui (1972–1990), Minister of Education (1984–1987), Minister of Foreign Affairs (1987–1990), chancellor of Victoria University of Wellington (2000–2002), High Commissioner to the United Kingdom (2002–2005) (born 1936). 19 January – David Johnston, disaster researcher (Massey University) (born 1966). 20 January – Richard Hipa, Niuean public servant and politician, Secretary of Government (2008–2017), Member of the Niue Assembly (2020–2023) (born 1957). 21 January Diana Beaglehole, historian (born 1938).
=== Sabbatical leave (1913/1914) === In 1913/1914 Robertson took 12 months sabbatical leave from the University of California. He spent four months in Adelaide, during which time he delivered two lectures: "Some Factors in the Cell Growth of Tumors [sic]", to the Microscopical Society of South Australia on 22 July 1913, and "Some Economic Aspects of Scientific Research", to the Science Association of the Adelaide University on 6 August 1913. On 12 November 1913, he submitted a 17-page report, Report on the Scope and Administration of an Institute for Scientific Research in Australia (BR.13), to the South Australian branch of the British Science Guild. The Guild's Report, with Robertson's report appended to it, was immediately given to Patrick "Paddy" McMahon Glynn, the Member for Angas, and Minister for Foreign Affairs, for him to directly hand it on to the Prime Minister, Joseph Cook. According to George Currie and John Graham (GC.1, pp.8–9), there is no evidence that Robertson's (1913) report ever reached the Prime Minister (or any other Minister) at that time. Robertson then travelled widely throughout Europe. In March 1914 he met up with Ivan Pavlov in Russia, and Pavlov gave him a personal tour of his laboratories at the Institute of Experimental Medicine in Saint Petersburg.
Lord Advocate Dorothy Bain, Scotland's most senior lawyer, apologises to victims of the Post Office scandal, saying they were let down by the justice system. Finance Secretary Shona Robison confirms that the Scottish Government is to cut at least 1,200 funded university places as they cannot afford to continue paying for additional places created during the COVID-19 pandemic. 17 January – The UK government is seeking legal expenses from the Scottish Government over its challenge against the veto of the Gender Recognition Reform (Scotland) Bill. 18 January – Community Safety Minister Siobhian Brown announces that Scotland will introduce legislation to ban the sale, breeding and abandonment of American XL bully dogs, replicating the law for England and Wales, at a date to be confirmed later. Nuns Sister Sarah McDermott and Sister Eileen Igoe, and carer Margaret Hughes, who mistreated children at Smyllum Park, an orphanage in Lanark from 1969 until 1981 when it closed, are each sentenced to three years in prison. Helen Goss, the mother of an eleven-year-old girl from Aberdeenshire with long COVID, launches legal action against NHS Grampian for what she says are the health board's "multiple failings" in the care and treatment of her daughter. 21 January – Scotland's First Minister, Humza Yousaf, tells the BBC's Sunday with Laura Kuenssberg he is willing to work with Sir Keir Starmer if he becomes prime minister after the next general election. ScotRail cancels all services from 7pm until after the following day's rush hour because of high winds caused by Storm Isha.
== Side effects == Side effects are similar to other prostaglandin analogs applied to the eye. The most common one is conjunctival hyperemia, which occurs in more than 10% of patients. Other effects include blurred vision, eye and eyelid redness, eye burning or other discomfort, and permanent darkening of the iris to brown. Occasional adverse effects (in less than 1% of patients) are headache and nausea. Some side effects are specific to the cosmetic formulation, which is applied to the skin at the base of the eyelash rather than instilled into the eye. These include infection if the one-time applicators are reused, and darkening of the eyelid or of the area beneath the eye. Research suggests that wiping the eye with an absorbent pad after the administration of eye drops can result in shorter eyelashes and a lesser chance of hyperpigmentation in the eyelid, compared to not wiping off excess fluid.
Vericrustacea ("true crustaceans")—Branchiopoda, Copepoda, Malacostraca, Thecostraca. Multicrustacea ("numerous crustaceans")—Copepoda, Malacostraca, Thecostraca. Communostraca ("common shelled ones")—Malacostraca, Thecostraca. Miracrustacea ("surprising crustaceans")—Cephalocarida, Remipedia, Hexapoda. Xenocarida ("strange shrimp")—Cephalocarida, Remipedia. Of these proposed clades, only Multicrustacea was confirmed in later molecular studies.
Sources: en.wikipedia.org
=== Renaming === The laboratory was renamed Lawrence Livermore Laboratory (LLL) in 1971. On October 1, 2007 Lawrence Livermore National Security, LLC (LLNS) assumed management of LLNL from the University of California, which had exclusively managed and operated the Laboratory since its inception 55 years before. The laboratory was honored in 2012 by having the synthetic chemical element livermorium named after it. The LLNS takeover of the laboratory has been controversial. In May 2013, an Alameda County jury awarded over $2.7 million to five former laboratory employees who were among 430 employees LLNS laid off during 2008. The jury found that LLNS breached a contractual obligation to terminate the employees only for "reasonable cause." The five plaintiffs also have pending age discrimination claims against LLNS, which will be heard by a different jury in a separate trial. There are 125 co-plaintiffs awaiting trial on similar claims against LLNS. The May 2008 layoff was the first layoff at the laboratory in nearly 40 years. On March 14, 2011, the City of Livermore officially expanded the city's boundaries to annex LLNL and move it within the city limits. The unanimous vote by the Livermore city council expanded Livermore's southeastern boundaries to cover 15 land parcels covering 1,057 acres (4.28 km2) that comprise the LLNL site. The site was formerly an unincorporated area of Alameda County. The LLNL campus continues to be owned by the federal government.
The engine had a physics system permitting new features, such as monsters hurling corpses at the player or dying characters realistically crumbling into pieces, instead of requiring pre-built animations. Although Troika had ignored first-person engines due to technical limitations, such as a low polygon count and limited texture memory, as the technology improved, it thought it could create a real-time action game without sacrificing the immersion and story of a role-playing game. Describing the choice of developing a game based on the existing White Wolf property over creating their own, Boyarsky said that although an original property lacked the constraints of an existing one, the downside was that it had not been tested and could be rejected by its potential audience; an existing property was proven. Troika tried to stay as close as possible to the White Wolf rules while reducing the number of abilities and disciplines to those relevant to Bloodlines gameplay.
=== Other illnesses === According to a 2020 meta-analysis of 48 clinical trials, Pioglitazone and Roux-en-Y gastric bypass surgery were the two most effective treatments for non-alcoholic steatohepatitis; the analysis' authors based this conclusion on improvements to the non-alcoholic fatty liver disease scores of trial participants. A 2021 meta-analysis of three clinical trials found that Pioglitazone had not been proven effective to treat Alzheimer's disease.
==== August 2008 ==== Nezavisimaya Gazeta reported in June 2008 that when Chechen peacekeepers from Vostok Battalion began serving in South Ossetia in the autumn of 2007, they began arresting armed people with fake peacekeeping IDs. However, the Chechens were soon ordered to cease the arrest of the impostors and armed people with unknown affiliations were now freely roaming South Ossetia. On 4 August 2008, Life.ru reported that after the end of the "Kavkaz 2008" exercises, the paratroopers from Pskov remained to occupy the key positions on the Roki and Mamison passes on the border. Several battalions of 58th Army were deployed close to the border and the South Ossetian sources told the newspaper that the deployment of troops began on the night of 2–3 August 2008. Life.ru reported, "The deployment of the Russian military hardware near the Roki Tunnel will allow as soon as possible to move troops to help the peacemaking forces." On 6 August 2008, OsRadio reported that the volunteers were also arriving in Tskhinvali from Moscow. On 26 September 2008, Trud reported on the special battalion Vostok. One member of the battalion Khamzat said, "See what the "Red Star" wrote about us: Volunteers from neighboring republics arrive in South Ossetia. So we are volunteers?!" Khamzat added, "We are the regular subunit of 291-th Regiment of 42nd Guards Motor Rifle Division of the North Caucasus Military District. And we only act on orders." On 8 August 2008, Nezavisimaya Gazeta published an article by journalist who had spent previous three days in Chechnya.
== External links == Myiasis, reviewed and published by WikiVet Exotic Myiasis, University of Sydney Department of Medical Entomology Identification key to species of myiasis-causing fly larvae, Natural History Museum (London) Parasitic Insects, Mites and Ticks: Genera of Medical and Veterinary Importance: Botflies
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.
PT-141 was the internal development code used during early research and it persists in older publications, conference abstracts, and informal listings. The code and the approved name refer to the same molecule. Its continued use reflects habit in the literature rather than any difference in substance.
No. The intranasal form was studied in trials but was never approved, and absorption through the nasal route varies considerably between individuals. Approved labelling covers a subcutaneous injection only. Any nasal product sold outside regulated channels falls outside verified manufacturing.
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.